Management of Acute Gouty Flare in Patients with Renal Impairment

Immediate Treatment Selection

The European League Against Rheumatism recommends oral corticosteroids, specifically prednisolone 30-35 mg daily for 3-5 days, as the safest and most effective first-line treatment for acute gout flare in patients with renal impairment 1, 2
Corticosteroids have equivalent efficacy to NSAIDs but superior safety in patients with chronic kidney disease (CKD) 1
The use of oral corticosteroids avoids the nephrotoxicity of NSAIDs and the dose-adjustment complexities of colchicine in renal impairment 1, 2
If corticosteroids are contraindicated, colchicine can be used but requires careful dosing, with a loading dose of 1 mg followed by 0.5 mg one hour later (only if within 12 hours of symptom onset) 1, 2
Intra-articular corticosteroid injection is highly effective for acute gout flare in a single joint, avoiding systemic drug exposure and renal concerns entirely 1, 2, 3

The American College of Rheumatology recommends verifying that the patient is not taking strong P-glycoprotein inhibitors (cyclosporine) or CYP3A4 inhibitors (clarithromycin, ketoconazole, verapamil, HIV protease inhibitors) before prescribing colchicine 1
If the patient is taking these medications, colchicine is absolutely contraindicated 1

The European League Against Rheumatism recommends not initiating urate-lowering therapy (allopurinol, febuxostat) during an acute flare 4, 3
If the patient is already on urate-lowering therapy, it should be continued, not stopped 4, 3
High-dose colchicine regimens should not be used due to the risk of toxicity 1

Patient education is essential, explaining that acute treatment does not prevent future attacks, and discussing the need for long-term urate-lowering therapy if recurrent flares, tophi, or chronic gout occur 2, 4, 3
Lifestyle counseling should include weight loss if obese, avoiding alcohol, eliminating sugar-sweetened beverages, and reducing red meat and seafood intake 2, 4
The patient should be assessed for initiation of urate-lowering therapy, with a target serum uric acid level of <6 mg/dL long-term 2, 4, 3
When urate-lowering therapy is started, prophylaxis with low-dose colchicine (0.5 mg daily, adjusted for renal function) for 6 months is mandatory to prevent mobilization flares 2, 5, 3

Renal impairment in gout patients is associated with hypertension, diabetes, and cardiovascular disease, and these comorbidities should be screened for 1, 2
Medications such as thiazide or loop diuretics should be reviewed and switched to losartan or calcium channel blockers if possible, to avoid worsening hyperuricemia 4
Hyperlipidemia should be screened for, and fenofibrate considered due to its uricosuric properties 4